# Dapagliflozin Therapy In Cardiac Surgery

> **NCT05621551** · PHASE4 · COMPLETED · sponsor: **China National Center for Cardiovascular Diseases** · enrollment: 178 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2
- Cardiac Surgery

## Interventions

- **DRUG:** Dapagliflozin

## Key facts

- **NCT ID:** NCT05621551
- **Lead sponsor:** China National Center for Cardiovascular Diseases
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-11
- **Primary completion:** 2024-06-01
- **Final completion:** 2025-06-01
- **Target enrollment:** 178 (ACTUAL)
- **Last updated:** 2025-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05621551

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05621551, "Dapagliflozin Therapy In Cardiac Surgery". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT05621551. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*